Characterization of the SARS-CoV-2 B.1.621 (Mu) variant

• Published in: Science translational medicine Vol. 14; no. 657; p. eabm4908
• Main Authors: Halfmann, Peter J, Kuroda, Makoto, Armbrust, Tammy, Theiler, James, Balaram, Ariane, Moreno, Gage K, Accola, Molly A, Iwatsuki-Horimoto, Kiyoko, Valdez, Riccardo, Stoneman, Emily, Braun, Katarina, Yamayoshi, Seiya, Somsen, Elizabeth, Baczenas, John J, Mitamura, Keiko, Hagihara, Masao, Adachi, Eisuke, Koga, Michiko, McLaughlin, Matthew, Rehrauer, William, Imai, Masaki, Yamamoto, Shinya, Tsutsumi, Takeya, Saito, Makoto, Friedrich, Thomas C, O'Connor, Shelby L, O'Connor, David H, Gordon, Aubree, Korber, Bette, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States 10.08.2022
• Subjects: Antibodies, Neutralizing; Antibodies, Viral; COVID-19 - therapy; COVID-19 Serotherapy; Humans; Immunization, Passive; Membrane Glycoproteins - genetics; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus - genetics; Vaccination; Viral Envelope Proteins - genetics

The SARS-CoV-2 B.1.621 (Mu) variant emerged in January 2021 and was categorized as a variant of interest by the World Health Organization in August 2021. This designation prompted us to study the sensitivity of this variant to antibody neutralization. In a live virus neutralization assay with serum...